What is SynCardia Systems LLC?
SynCardia Systems LLC, based in Tucson, Arizona, is recognized as the developer and manufacturer of the world's first and only FDA, Health Canada, and CE approved Total Artificial Heart. This life-saving device serves as a crucial bridge to transplant for individuals suffering from biventricular heart failure, enabling them to survive until a suitable donor heart becomes available. Beyond the Total Artificial Heart, the company also produces the Freedom portable driver, which empowers clinically stable patients to leave the hospital and live at home while awaiting a transplant, significantly improving their quality of life during a critical period.
How much funding has SynCardia Systems LLC raised?
SynCardia Systems LLC has raised a total of $42.3M across 7 funding rounds:
Series B
$3.7M
Series D
$10.3M
Private Equity
$5M
Debt
$14M
Private Equity
$6.4M
Debt
$1M
Debt
$1.9M
Series B (2004): $3.7M, investors not publicly disclosed
Series D (2009): $10.3M led by Highway 12 Ventures
Private Equity (2011): $5M, investors not publicly disclosed
Debt (2013): $14M featuring SWK Holdings and Athyrium Capital Management
Private Equity (2014): $6.4M, investors not publicly disclosed
Debt (2020): $1M with participation from PPP
Debt (2021): $1.9M led by PPP
Key Investors in SynCardia Systems LLC
Highway 12 Ventures
Highway 12 Ventures is a venture capital firm that has participated in SynCardia's funding rounds, likely focusing on early-stage to growth-stage companies within the technology and healthcare sectors.
SWK Holdings
SWK Holdings is a life science specialty finance company that provides capital solutions to healthcare sector companies, indicating a strategic interest in SynCardia's medical device technology.
Athyrium Capital Management
Athyrium Capital Management is an investment platform specializing in structured investments within the global healthcare sector, suggesting a focus on companies with significant market potential and innovative solutions like SynCardia's artificial heart.
What's next for SynCardia Systems LLC?
The substantial enterprise-level funding and recent strategic investment indicate a strong confidence in SynCardia Systems' technology and market potential. This capital infusion is likely to fuel further research and development, enhance manufacturing capabilities, and expand market reach for their Total Artificial Heart and portable driver solutions. The company's focus on addressing a critical unmet need in the medical device sector positions it for continued growth and impact in the cardiovascular health landscape.
See full SynCardia Systems LLC company page
